Ultime notizie per OptiNose (NASDAQ:OPTN) Azioni

OptiNose

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

OptiNose Inc

News

Contracts

CLSK

Canaan To Provide CleanSpark With 3800 Avalon A1566I Immersion Cooling Miners; Financial Details Not Disclosed

Biotech

General

Novo Nordisk's Semaglutide 2.4 mg Achieves Primary Endpoints In Essence Trial, Showing Significant Improvement In Liver Fibrosis And MASH Resolution At Week 72 With Positive Safety Profile; Regulatory Filings Planned For U.S. And EU In 1H 2025, With Detailed Results To Be Presented This Year And Part 2 Readout Expected In 2029

<p>TD Cowen  analyst John Blackledge   maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $240.</p>


Price Target

Analyst Ratings

AMZN

TD Cowen Maintains Buy on Amazon.com, Raises Price Target to $240

Financing

FCEL

FuelCell Energy Closes On Project Debt Financing Transaction With EXIM For Gyeonggi Green Energy Projects; Co. To Receive ~$9.4M In Debt Financing

<p>Chardan Capital  analyst Keay Nakae   maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $300 price target.</p>


ALNY

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target

WIIM

BFLY

Butterfly Network shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

TILE

Interface shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net sales guidance above estimates.

<p>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>), is delighted to announce the appointment of Rúben Amorim as Head Coach of the men's first team, subject to work visa requirements.</p>
<p>He will join until June 2027 with a club option of an additional year once he has fulfilled his obligations to his current club. He will join Manchester United on Monday 11 November.</p>
<p>Rúben is one of the most exciting and highly rated young coaches in European football. Highly decorated as both a player and coach, his titles include winning the Primeira Liga twice in Portugal with Sporting CP; the first of which was the club's first title in 19 years.</p>
<p>Ruud van Nistelrooy will continue to take charge of the team until Rúben joins.</p>


Management

MANU

Manchester United Announces The Appointment Of Rúben Amorim As Head Coach; Ruud Van Nistelrooy Will Continue To Take Charge Of The Team Until Rúben Joins

<p>TD Cowen  analyst Gautam Khanna   downgrades Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) from Buy to Hold and announces $180 price target.</p>


Downgrades

TD Cowen Downgrades Huntington Ingalls Indus to Hold, Announces $180 Price Target

<h3>Gainers</h3>
<ul>
<li><strong>Wayfair</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) shares rose 15.0% to $49.25 during Friday's pre-market session. The market value of their outstanding shares is at $6.0 billion. As per the press release, Q3 earnings came out today. </li>
<li><strong>Phoenix Motor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares rose 14.56% to $0.52. The market value of their outstanding shares is at $19.3 million. The company's, Q2 earnings came out yesterday. </li>
<li><strong>Fly-E Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) stock moved upwards by 7.6% to $0.75. The market value of their outstanding shares is at $18.3 million. </li>
<li><strong>Amazon.com</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) stock moved upwards by 7.29% to $199.99. The company's market cap stands at $2.0 trillion. As per the press release, Q3 earnings came out yesterday. </li>
<li><strong>Canoo</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) shares rose 7.0% to $0.81. The market value of their outstanding shares is at $70.3 million. </li>
<li><strong>Tokyo Lifestyle</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) shares moved upwards by 6.08% to $0.48. The company's market cap stands at $20.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Visionary Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) stock decreased by 12.9% to $1.08 during Friday's pre-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li><strong>Ambow Education Holding</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares declined by 11.26% to $1.42. The company's market cap stands at $4.0 million. </li>
<li><strong>Hall Of Fame Resort</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) stock fell 8.49% to $1.51. The company's market cap stands at $9.8 million. </li>
<li><strong>Lead Real Estate Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) shares declined by 6.96% to $2.14. The market value of their outstanding shares is at $29.1 million. </li>
<li><strong>BJ's Restaurants</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) stock declined by 5.67% to $34.99. The company's market cap stands at $810.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li><strong>J-Long Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) shares fell 5.6% to $0.54. The company's market cap stands at $16.9 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

AMBO

BJRI

FLYE

GOEV

HOFV

TKLF

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Wayfair</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) shares moved upwards by 15.0% to $49.25 during Friday's pre-market session. The market value of their outstanding shares is at $6.0 billion. As per the press release, Q3 earnings came out today. </li>
<li><strong>Phoenix Motor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares moved upwards by 14.56% to $0.52. The market value of their outstanding shares is at $19.3 million. The company's, Q2 earnings came out yesterday. </li>
<li><strong>Fly-E Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares rose 7.6% to $0.75. The market value of their outstanding shares is at $18.3 million. </li>
<li><strong>Amazon.com</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) stock rose 7.29% to $199.99. The market value of their outstanding shares is at $2.0 trillion. As per the press release, Q3 earnings came out yesterday. </li>
<li><strong>Canoo</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) stock rose 7.0% to $0.81. The market value of their outstanding shares is at $70.3 million. </li>
<li><strong>Tokyo Lifestyle</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) stock rose 6.08% to $0.48. The market value of their outstanding shares is at $20.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Visionary Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) shares declined by 12.9% to $1.08 during Friday's pre-market session. The company's market cap stands at $4.0 million. </li>
<li><strong>Ambow Education Holding</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares fell 11.26% to $1.42. The market value of their outstanding shares is at $4.0 million. </li>
<li><strong>Hall Of Fame Resort</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) shares fell 8.49% to $1.51. The market value of their outstanding shares is at $9.8 million. </li>
<li><strong>Lead Real Estate Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) shares declined by 6.96% to $2.14. The market value of their outstanding shares is at $29.1 million. </li>
<li><strong>BJ's Restaurants</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) stock decreased by 5.67% to $34.99. The company's market cap stands at $810.1 million. The company's, Q3 earnings came out yesterday. </li>
<li><strong>J-Long Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) stock fell 5.6% to $0.54. The company's market cap stands at $16.9 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


<h3>Gainers</h3>
<ul>
<li><strong>Envoy Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares increased by 66.0% to $4.4 during Friday's pre-market session. The company's market cap stands at $86.8 million. </li>
<li><strong>Theriva Biologics</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock rose 43.83% to $2.1. The market value of their outstanding shares is at $2.8 million. </li>
<li><strong>Athira Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares rose 26.13% to $0.54. The market value of their outstanding shares is at $20.6 million. </li>
<li><strong>Pro-Dex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 18.06% to $36.62. The company's market cap stands at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Molecular Partners</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 16.79% to $6.26. The market value of their outstanding shares is at $230.5 million. </li>
<li><strong>ChromaDex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock moved upwards by 16.04% to $4.05. The market value of their outstanding shares is at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Lexicon Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li><strong>OneMedNet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock declined by 10.37% to $0.77. The company's market cap stands at $18.3 million. </li>
<li><strong>Biofrontera</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 9.76% to $1.11. The company's market cap stands at $6.1 million. </li>
<li><strong>Trinity Biotech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li><strong>bioAffinity Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li><strong>Matinas BioPharma Hldgs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 8.07% to $0.57. The market value of their outstanding shares is at $2.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ATHA

BFRI

BIAF

CDXC

Envoy Medical, Inc. - Class A Common Stock

COCH

LXRX

MOLN

MTNB

ONMD

PDEX

TOVX

TRIB

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Envoy Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 66.0% to $4.4 during Friday's pre-market session. The market value of their outstanding shares is at $86.8 million. </li>
<li><strong>Theriva Biologics</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 43.83% to $2.1. The company's market cap stands at $2.8 million. </li>
<li><strong>Athira Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 26.13% to $0.54. The company's market cap stands at $20.6 million. </li>
<li><strong>Pro-Dex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 18.06% to $36.62. The market value of their outstanding shares is at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Molecular Partners</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 16.79% to $6.26. The company's market cap stands at $230.5 million. </li>
<li><strong>ChromaDex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 16.04% to $4.05. The company's market cap stands at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Lexicon Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock decreased by 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li><strong>OneMedNet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 10.37% to $0.77. The market value of their outstanding shares is at $18.3 million. </li>
<li><strong>Biofrontera</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares declined by 9.76% to $1.11. The market value of their outstanding shares is at $6.1 million. </li>
<li><strong>Trinity Biotech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares fell 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li><strong>bioAffinity Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li><strong>Matinas BioPharma Hldgs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock declined by 8.07% to $0.57. The company's market cap stands at $2.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


<h3>Gainers</h3>
<ul>
<li><strong>Nuburu</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) stock rose 21.1% to $0.55 during Friday's pre-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li><strong>Interface</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) stock increased by 14.48% to $20.0. The company's market cap stands at $1.1 billion. As per the press release, Q3 earnings came out today. </li>
<li><strong>Amprius Technologies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) stock moved upwards by 10.37% to $1.49. The company's market cap stands at $157.6 million. </li>
<li><strong>MasTec</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) shares increased by 8.21% to $132.99. The company's market cap stands at $10.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li><strong>Perma-Fix Envirn Servs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) shares rose 8.04% to $14.5. The market value of their outstanding shares is at $228.9 million. </li>
<li><strong>Eos Energy Enterprises</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock increased by 7.39% to $3.34. The market value of their outstanding shares is at $723.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>MDU Resources Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDU#NYSE">MDU</a>) stock declined by 30.8% to $19.98 during Friday's pre-market session. The market value of their outstanding shares is at $4.0 billion. </li>
<li><strong>Advent Technologies Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) shares fell 15.87% to $1.99. The market value of their outstanding shares is at $5.2 million. </li>
<li><strong>1847 Holdings</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares decreased by 12.48% to $0.46. </li>
<li><strong>YY Group Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) stock decreased by 7.59% to $1.34. The company's market cap stands at $46.1 million. </li>
<li><strong>Solidion Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock declined by 6.76% to $0.45. The company's market cap stands at $41.7 million. </li>
<li><strong>nVent Electric</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) stock fell 5.66% to $70.36. The market value of their outstanding shares is at $11.6 billion. As per the news, the Q3 earnings report came out today.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMPX

BURU

EFSH

EOSE

PESI

YYGH

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Nuburu</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) shares increased by 21.1% to $0.55 during Friday's pre-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li><strong>Interface</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares moved upwards by 14.48% to $20.0. The company's market cap stands at $1.1 billion. The company's, Q3 earnings came out today. </li>
<li><strong>MasTec</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) shares rose 8.21% to $132.99. The market value of their outstanding shares is at $10.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li><strong>Perma-Fix Envirn Servs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) shares increased by 8.04% to $14.5. The market value of their outstanding shares is at $228.9 million. </li>
<li><strong>Eos Energy Enterprises</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock moved upwards by 7.39% to $3.34. The market value of their outstanding shares is at $723.7 million. </li>
<li><strong>Enviri</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRI#NYSE">NVRI</a>) shares increased by 6.91% to $8.19. The market value of their outstanding shares is at $656.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>MDU Resources Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDU#NYSE">MDU</a>) shares declined by 30.8% to $19.98 during Friday's pre-market session. The company's market cap stands at $4.0 billion. </li>
<li><strong>Advent Technologies Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) stock decreased by 15.87% to $1.99. The market value of their outstanding shares is at $5.2 million. </li>
<li><strong>1847 Holdings</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares fell 12.48% to $0.46. </li>
<li><strong>YY Group Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) stock decreased by 7.59% to $1.34. The company's market cap stands at $46.1 million. </li>
<li><strong>Solidion Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock decreased by 6.76% to $0.45. The market value of their outstanding shares is at $41.7 million. </li>
<li><strong>nVent Electric</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) shares decreased by 5.66% to $70.36. The market value of their outstanding shares is at $11.6 billion. The company's, Q3 earnings came out today.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NVRI

<h3>Gainers</h3>
<ul>
<li><strong>Atlassian</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares rose 20.9% to $228.0 during Friday's pre-market session. The market value of their outstanding shares is at $59.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Cyngn</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares rose 8.57% to $3.8. The company's market cap stands at $7.7 million. </li>
<li><strong>GCT Semiconductor Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) shares increased by 7.79% to $2.49. The market value of their outstanding shares is at $117.7 million. </li>
<li><strong>Veea</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>) stock rose 7.61% to $3.39. The company's market cap stands at $120.7 million. </li>
<li><strong>Semilux International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELX#NASDAQ">SELX</a>) stock increased by 7.45% to $1.77. The company's market cap stands at $66.2 million. </li>
<li><strong>HeartCore Enterprises</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) shares moved upwards by 6.79% to $1.1. The market value of their outstanding shares is at $22.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Ostin Technology Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined by 10.0% to $0.45 during Friday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li><strong>SMX (Security Matters)</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) stock declined by 7.87% to $0.35. The market value of their outstanding shares is at $1.0 million. </li>
<li><strong>Iveda Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock fell 7.56% to $1.59. The company's market cap stands at $3.5 million. </li>
<li><strong>Phunware</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) shares declined by 6.51% to $6.61. The market value of their outstanding shares is at $74.9 million. </li>
<li><strong>Kopin</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) stock declined by 4.88% to $0.74. The market value of their outstanding shares is at $117.6 million. </li>
<li><strong>CCSC Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock decreased by 4.55% to $2.1. The company's market cap stands at $24.3 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CCTG

GCTS

HTCR

IVDA

KOPN

PHUN

SELX

TEAM

VEEA

12 Information Technology Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Atlassian</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares increased by 20.9% to $228.0 during Friday's pre-market session. The company's market cap stands at $59.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Cyngn</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares moved upwards by 8.57% to $3.8. The company's market cap stands at $7.7 million. </li>
<li><strong>GCT Semiconductor Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) shares moved upwards by 7.79% to $2.49. The market value of their outstanding shares is at $117.7 million. </li>
<li><strong>Veea</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>) stock moved upwards by 7.61% to $3.39. The company's market cap stands at $120.7 million. </li>
<li><strong>Semilux International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELX#NASDAQ">SELX</a>) shares rose 7.45% to $1.77. The company's market cap stands at $66.2 million. </li>
<li><strong>HeartCore Enterprises</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) shares rose 6.79% to $1.1. The market value of their outstanding shares is at $22.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Ostin Technology Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock declined by 10.0% to $0.45 during Friday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li><strong>SMX (Security Matters)</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) stock declined by 7.87% to $0.35. The company's market cap stands at $1.0 million. </li>
<li><strong>Iveda Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) shares declined by 7.56% to $1.59. The company's market cap stands at $3.5 million. </li>
<li><strong>Phunware</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) stock fell 6.51% to $6.61. The market value of their outstanding shares is at $74.9 million. </li>
<li><strong>Kopin</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) stock fell 4.88% to $0.74. The market value of their outstanding shares is at $117.6 million. </li>
<li><strong>CCSC Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock declined by 4.55% to $2.1. The market value of their outstanding shares is at $24.3 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


<p>Piper Sandler  analyst Rob Owens   maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Overweight and raises the price target from $225 to $265.</p>


Piper Sandler Maintains Overweight on Atlassian, Raises Price Target to $265

<p>TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) sees FY2025 sales of $14.422 billion.</p>


Guidance

TTDKY

TDK Sees FY2025 Sales JPY 2120B; Net profit JPY 160B.

<p>BTIG  analyst Clark Lampen   maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Buy and raises the price target from $51 to $56.</p>


RBLX

BTIG Maintains Buy on Roblox, Raises Price Target to $56

Lake Street analyst Thomas Flaten maintained a Buy rating on Optinose (OPTN – Research Report) today. The company's shares closed yesterday at $1.0...

Lake Street Sticks to Its Buy Rating for Optinose (OPTN)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The stock market rally has been showing no sign of stopping, and while most of it has been driven by Big Tech, it is worth looking into some little-known <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>. These stocks usually see huge breakouts and trade at big premiums during bullish rallies. We haven&rsquo;t seen that happen across most penny stocks just yet, but I think it&rsquo;s a good reason to buy up some high-potential names if you are willing to stomach the risks.</p>



<p>Of course, many of these penny stocks are more than just short- to mid-term plays. Most of these up-and-coming firms have huge growth runways, and analysts expect explosive growth over the next decade. If they execute as expected, I believe it is possible that they could turn a $10k investment into something life-changing. Let&rsquo;s take a look!</p>



<h2>OptiNose (OPTN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div><p><strong>OptiNose</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/optn-stock-quote/"><strong>OPTN</strong></a>) is a specialty pharmaceutical company focused on developing products for patients with diseases treated by otolaryngologists and allergists. I&rsquo;ve been closely watching this little-known penny stock, and I believe it could be a potential hidden gem for risk-tolerant investors.</p>



<p>Their lead product, XHANCE, has shown strong efficacy in treating chronic sinusitis, which, according to their market research, is a key driver of prescribing behavior.</p>



<p>OptiNose is admittedly a speculative bet, but I think the potential payoff could be substantial. The stock has been stuck trading around the $1 level for over a year, but with these promising developments, I wouldn&rsquo;t be surprised to see a breakout if they can execute well.</p>



<p>What I particularly like about OptiNose is its solid and rapidly growing sales base. Analysts are projecting revenue to skyrocket from <a href="https://seekingalpha.com/symbol/OPTN/earnings/estimates" target="_blank">$92 million in 2024 to $342 million by 2028</a>, with profitability expected by 2026.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-9.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/07/chart-9.png" alt="penny stocks: OptiNose operating profits"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>If everything goes according to plan, the stock is trading at just 3 times 2027 earnings estimates right now.</p>



<p>Of course, the key question is whether their growth plans will play out as hoped. Biotech and pharma startups are always a risky bet. But OptiNose seems to have weathered the worst and has a strong foundation upon which to build. This beaten-down stock could be a hidden multibagger in the making. Just be sure to do your own diligence.</p>



<h2>Unusual Machines (UMAC)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2019/04/dronesmsn-300x165.jpg" alt=""><div>Source: Shutterstock</div></div><p><strong>Unusual Machines</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/umac-stock-quote/"><strong>UMAC</strong></a>) manufactures drones and drone components. I&rsquo;m very bullish on drone startups like Unusual Machines. There simply aren&rsquo;t enough of these companies in the U.S. right now, especially ones focused on producing inexpensive military drones for reconnaissance and combat purposes.</p>



<p>Most of those cheaper military drones are currently mass-produced in China and Russia. Meanwhile, the U.S. relies on a handful of giant defense contractors making very expensive drones. I believe this supply chain vulnerability is becoming increasingly apparent to governments worldwide. They&rsquo;re scrambling to ink deals with promising upstart drone makers to diversify their sources.</p>



<p>That&rsquo;s where Unusual Machines comes in. Sure, with just <a target="_blank" href="https://www.stocktitan.net/news/UMAC/">$619,000 in sales</a> (the sales were made in just 45 days) last quarter, it&rsquo;s tiny and unprofitable. However, after a recent $5 million IPO and acquiring key operating units like Fat Shark and Rotor Riot, this <strong>Red Cat Holdings</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rcat-stock-quote/"><strong>RCAT</strong></a>) spinoff has big potential, in my view. Management is moving fast to start churning out NDAA-compliant drone parts from its new Orlando headquarters.</p>



<p>If it can secure those critical &ldquo;Blue UAS&rdquo; certifications soon, lucrative government contracts could follow and really jumpstart growth. Of course, this is an extremely speculative play. I&rsquo;m banking on a rosy future that may not materialize. UMAC is only suitable if you seriously want to turn $10k into a million and take on the risks that come with it.</p>



<h2>High Tide (HITI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png" alt="scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks"><div>Source: Chokniti-Studio / Shutterstock.com</div></div><p><strong>High Tide</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hiti-stock-quote/"><strong>HITI</strong></a>) operates as a retail-focused cannabis company. I covered this little-known penny stock over a year ago, and it&rsquo;s already up by a whopping 80% since then, but I believe High Tide still has substantial upside potential. High Tide generated <a target="_blank" href="https://www.tipranks.com/news/company-announcements/high-tide-achieves-record-q2-financial-milestones">9.4 million CAD in free cash flow in Q2</a>, more than the prior two quarters combined. It&rsquo;s a rare gem in the cannabis space that isn&rsquo;t burning cash and is on the cusp of sustained profitability.</p>



<p>Once High Tide firmly establishes consistent earnings and accelerates its expansion, I expect this stock could deliver multibagger returns from current levels based solely on the Canadian market opportunity. However, the real game-changer would be U.S. federal cannabis legalization. High Tide already has a footprint in the U.S. but operates with restraints.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-10.png"><img width="1226" height="741" src="https://investorplace.com/wp-content/uploads/2024/07/chart-10.png" alt="High Tide sales by region chart"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>If it can replicate its Canadian success in a market 10 times larger, this under-the-radar stock could turn a $10k investment into something much more meaningful.</p>



<h2>Blackline Safety (BLKLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/fr_firstindustrial1600-300x169.png" alt="Back View of the Head of the Project Holds Laptop and Discussing Product Details with Chief Engineer while They Walk Through Modern Factory., FR rents out these spaces in the U.S."><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Blackline Safety</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/blklf-stock-quote/"><strong>BLKLF</strong></a>) is a Canadian industrial safety company that is riding the wave of onshoring and industrialization. Shares have already surged 150% from their late-2022 trough, but I think there&rsquo;s plenty of room for this rebound to run. The stock still trades nearly 40% below its February 2020 peak despite the company being perfectly positioned to capitalize on the manufacturing renaissance in the U.S. and Canada.</p>



<p>As companies bring production closer to home, they must ensure their facilities meet the rigorous safety standards in these markets. That&rsquo;s where Blackline shines. Its connected safety technology is already seeing booming demand, with <a target="_blank" href="https://www.morningstar.com/news/business-wire/20240613677452/blackline-safety-reports-highest-quarterly-revenue-ever-q2-hits-316m-up-31-year-over-year">revenue jumping 31% YOY to a record $31.6 million</a> in Q2.</p>



<p>Blackline achieved this growth while also expanding its gross margins to 57% and slashing its cash burn by 78%. This tells me that as the company scales up to meet the surging need for industrial safety, its bottom line could boom.</p>



<p>So, while Blackline may be under the radar now, I believe it&rsquo;s a hidden gem that won&rsquo;t stay hidden for long.</p>



<h2>Talkspace (TALK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/talkspace-300x169.jpg" alt="The Talkspace (TALK) logo is displayed on a smartphone screen."><div>Source: Ben__Stevens / Shutterstock.com</div></div><p><strong>Talkspace</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/talk-stock-quote/"><strong>TALK</strong></a>) is a leading virtual behavioral health company that connects individuals with licensed therapists through its platform. While telemedicine stocks were all the rage during the COVID-19 pandemic, Talkspace&rsquo;s shares have been on a wild ride since going public. After a sharp decline, the stock surged nearly 500% from Q1 2023 to Q1 2024 before recently pulling back around 43%. I believe this presents an attractive entry point.</p>



<p>In Q1 2024, Talkspace delivered <a target="_blank" href="https://www.investing.com/news/stock-market-news/earnings-call-talkspace-reports-profitability-in-q1-with-revenue-growth-93CH-3427451">36% YOY revenue growth to $45.4 million</a> and achieved its first quarter of profitability with an $800,000 adjusted EBITDA. Management&rsquo;s execution on expanding covered lives, and driving utilization is clearly paying off. The recent Medicare launch in multiple states offers another significant growth catalyst.</p>



<p>With profits expected in 2025, along with a <a target="_blank" href="https://seekingalpha.com/symbol/TALK/earnings/estimates">projected 26% sales growth</a> in 2024 and 17-20% annual increases thereafter, I see ample room for upside. Talkspace is well-positioned to benefit from powerful tailwinds. This includes the destigmatization of mental health and younger generations preferring to do everything online.</p>



<h2>Kneat.com (KSIOF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p><strong>Kneat.com</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/ksiof-stock-quote/"><strong>KSIOF</strong></a>) provides software validation solutions for the life sciences industry. The stock has rebounded significantly, up 37% in the past six months alone. I believe Kneat is well-positioned to benefit from the plethora of biotech startups that need validation software to ensure compliance with industry regulations.</p>



<p>In Q1, Kneat&rsquo;s annual recurring revenue <a target="_blank" href="https://financialpost.com/globe-newswire/kneat-announces-record-revenue-for-first-quarter-2024">jumped an impressive 57% to 42.1 million CAD</a>. The gross profit margin expanded from 67% to a robust 74%, while operating expenses grew at a much more modest 17% pace compared to the 77% surge in Q1 2023.</p>



<p>Management noted they are landing major new customer wins across North America, Europe, and Asia, which are fueling the growth. However, the real potential lies in expanding these relationships over time. As Kneat becomes ingrained and trusted within organizations, it can multiply its revenue per customer.</p>



<p>GuruFocus&rsquo; DCF model believes the stock will compound through 2026.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-11.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/07/chart-11.png" alt="KSIOF gurufocus price"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><h2>One Stop Systems (OSS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/computers1600d-300x169.jpg" alt="a man working on a computer hard drive"><div>Source: Shutterstock</div></div><p><strong>One Stop Systems</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/oss-stock-quote/"><strong>OSS</strong></a>) designs and manufactures high-performance edge computing systems for AI and other applications. Despite seeing a <a target="_blank" href="https://www.marketbeat.com/stocks/NASDAQ/OSS/earnings/">24.6% YOY revenue decline to $12.65 million</a> in Q1 2024, I believe OSS is poised for a strong rebound as AI takes off.</p>



<p>The company has done a stellar job shifting its focus to the booming defense and commercial markets, especially for AI and machine learning at the edge. CEO Mike Knowles <a target="_blank" href="https://markets.businessinsider.com/news/stocks/one-stop-systems-oss-strong-buy-rating-on-ai-pivot-and-long-term-growth-potential-1033188679">noted</a> OSS has expanded its 5-year pipeline to over $1 billion, with 70% from multi-year platform opportunities that should drive more predictable revenue.</p>



<p>While the near-term upside may be limited as many AI/ML applications are still in development and testing phases, I&rsquo;m confident OSS is very well-positioned for the coming wave. HPC and enterprise computing needs are exploding as AI startups proliferate, and transformative systems like OpenAI&rsquo;s Sora could send demand soaring even higher.</p>



<p>OSS is admittedly a high-risk, high-reward bet in this nascent industry. But for investors willing to stomach the volatility, I believe getting in early on OSS&rsquo;s turnaround story could deliver incredible returns if the AI rally keeps charging ahead in the years to come.</p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a></em>.</p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/7-little-known-penny-stocks-that-can-turn-10k-into-1-million/">7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million

OptiNose GAAP EPS of -$0.05 beats by $0.03, revenue of $20.49M misses by $0.59M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>OptiNose</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/optn-stock-quote/"><strong>OPTN</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>OptiNose reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -8 cents.</li><li>The company reported revenue of $20.49 million.</li><li>This was 0.44% worse than the analyst estimate for revenue of $20.58 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/optn-stock-earnings-optinose-for-q2-of-2024/">OPTN Stock Earnings: OptiNose Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

OPTN Stock Earnings: OptiNose Beats EPS, Misses Revenue for Q2 2024

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Optinose (OPTN – Research Report), with a price target...

Optinose's XHANCE Poised for Market Expansion and Growth: A Buy Rating Review

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript

Optinose ( ($OPTN) ) has issued an announcement. Catherine Owen has stepped down from the Board of Directors at OptiNose, Inc., leaving amicably wi...

Catherine Owen Departs Optinose Board for CEO Role at Acadia

Optinose names Terry Kohler as CFO

Optinose ( ($OPTN) ) has shared an announcement. OptiNose, Inc. has appointed Terry Kohler, a seasoned biotech finance expert with over two decades...

OptiNose Names Terry Kohler New CFO with Incentive Grant

Lake Street analyst Thomas Flaten maintained a Buy rating on Optinose (OPTN – Research Report) today. The company's shares closed yesterday at $0.7...

Lake Street Sticks to Their Buy Rating for Optinose (OPTN)

BLKLF

HITI

KSIOF

OPTN

RCAT

TALK

UMAC

Press Releases

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

Earnings

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Health Care

Expanded Access to XHANCE with Addition to National Commercial Formularies

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

Comments

OptiNose

Notizie

Ultime notizie per OptiNose (NASDAQ:OPTN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO